143 related articles for article (PubMed ID: 9698269)
21. The chemotherapy of onchocerciasis XX: ivermectin in combination with albendazole.
Awadzi K; Addy ET; Opoku NO; Plenge-Bönig A; Büttner DW
Trop Med Parasitol; 1995 Dec; 46(4):213-20. PubMed ID: 8826100
[TBL] [Abstract][Full Text] [Related]
22. The impact of ivermectin treatment alone and when in parallel with Simulium neavei elimination on onchocerciasis in Uganda.
Ndyomugyenyi R; Tukesiga E; Büttner DW; Garms R
Trop Med Int Health; 2004 Aug; 9(8):882-6. PubMed ID: 15303993
[TBL] [Abstract][Full Text] [Related]
23. Use of the recombinant Onchocerca volvulus protein Ov20/OvS1 for the immunodiagnostic differentiation between onchocerciasis and mansonelliasis and for the characterization of hyperreactive onchocerciasis (sowda).
Mpagi JL; Büttner DW; Tischendorf FW; Erttmann KD; Brattig NW
Trop Med Int Health; 2000 Dec; 5(12):891-7. PubMed ID: 11169279
[TBL] [Abstract][Full Text] [Related]
24. Dependence of eosinophil granulocyte infiltration into nodules on the presence of microfilariae producing Onchocerca volvulus.
Wildenburg G; Krömer M; Büttner DW
Parasitol Res; 1996; 82(2):117-24. PubMed ID: 8825205
[TBL] [Abstract][Full Text] [Related]
25. Immunopathology of onchocerciasis: a role for eosinophils in onchocercal dermatitis and keratitis.
Pearlman E
Chem Immunol; 1997; 66():26-40. PubMed ID: 9103664
[TBL] [Abstract][Full Text] [Related]
26. [Molecular approaches to the control of onchocerciasis in Mexico].
Rodríguez-Pérez MA
Rev Latinoam Microbiol; 2005; 47(3-4):112-29. PubMed ID: 17061536
[TBL] [Abstract][Full Text] [Related]
27. Serum-dependent interaction of granulocytes with Onchocerca volvulus microfilariae in generalized and chronic hyper-reactive onchocerciasis and its modulation by diethylcarbamazine.
Medina-De la Garza CE; Brattig NW; Tischendorf FW; Jarrett JM
Trans R Soc Trop Med Hyg; 1990; 84(5):701-6. PubMed ID: 2278077
[TBL] [Abstract][Full Text] [Related]
28. Differences in eosinophil and neutrophil chemotactic responses in sowda and generalized form of onchocerciasis.
Rubio de Krömer MT; Medina-De la Garza CE; Brattig NW
Acta Trop; 1995 Sep; 60(1):21-33. PubMed ID: 8546035
[TBL] [Abstract][Full Text] [Related]
29. Individual host factors associated with Onchocerca volvulus microfilarial densities 15, 80 and 180 days after a first dose of ivermectin.
Pion SD; Grout L; Kamgno J; Nana-Djeunga H; Boussinesq M
Acta Trop; 2011 Sep; 120 Suppl 1():S91-9. PubMed ID: 20497765
[TBL] [Abstract][Full Text] [Related]
30. Humoral responses to a secretory Onchocerca volvulus protein: differences in the pattern of antibody isotypes to recombinant Ov20/OvS1 in generalized and hyperreactive onchocerciasis.
Mpagi JL; Büttner DW; Tischendorf FW; Erttmann KD; Brattig NW
Parasite Immunol; 2000 Sep; 22(9):455-60. PubMed ID: 10972852
[TBL] [Abstract][Full Text] [Related]
31. Immunocompetence may be important in the effectiveness of Mectizan (ivermectin) in the treatment of human onchocerciasis.
Ali MM; Mukhtar MM; Baraka OZ; Homeida MM; Kheir MM; Mackenzie CD
Acta Trop; 2002 Oct; 84(1):49-53. PubMed ID: 12387910
[TBL] [Abstract][Full Text] [Related]
32. Distribution of mast cells and their correlation with inflammatory cells around Onchocerca gutturosa, O. tarsicola, O. ochengi, and O. flexuosa.
Wildenburg G; Plenge-Bönig A; Renz A; Fischer P; Büttner DW
Parasitol Res; 1997; 83(2):109-20. PubMed ID: 9039692
[TBL] [Abstract][Full Text] [Related]
33. Ivermectin-facilitated immunity in onchocerciasis; activation of parasite-specific Th1-type responses with subclinical Onchocerca volvulus infection.
Soboslay PT; Lüder CG; Hoffmann WH; Michaelis I; Helling G; Heuschkel C; Dreweck CM; Blanke CH; Pritze S; Banla M
Clin Exp Immunol; 1994 May; 96(2):238-44. PubMed ID: 8187332
[TBL] [Abstract][Full Text] [Related]
34. Cell adherence to microfilariae of Onchocerca volvulus: a comparative study.
Williams JF; Ghalib HW; Mackenzie CD; Elkhalifa MY; Ayuya JM; Kron MA
Ciba Found Symp; 1987; 127():146-63. PubMed ID: 3595320
[TBL] [Abstract][Full Text] [Related]
35. [Short review of pathophysiology and therapeutic possibilities in onchocerciasis with reference to a case report].
Winkler S; Wenisch C; Wiesinger E; Breyer S; Graninger W
Wien Klin Wochenschr; 1994; 106(11):354-8. PubMed ID: 8053203
[TBL] [Abstract][Full Text] [Related]
36. Association of transient dermal mastocytosis and elevated plasma tryptase levels with development of adverse reactions after treatment of onchocerciasis with ivermectin.
Cooper PJ; Schwartz LB; Irani AM; Awadzi K; Guderian RH; Nutman TB
J Infect Dis; 2002 Nov; 186(9):1307-13. PubMed ID: 12402200
[TBL] [Abstract][Full Text] [Related]
37. The effect of ivermectin treatment on the antibody response to antigens of Onchocerca volvulus.
Gillespie AJ; Lustigman S; Rivas-Alcala AR; Bradley JE
Trans R Soc Trop Med Hyg; 1994; 88(4):456-60. PubMed ID: 7570844
[TBL] [Abstract][Full Text] [Related]
38. Identification of Onchocerca volvulus collagen as an antigen mainly recognized by antibodies in chronic hyper-reactive onchodermatitis (sowda).
Garate T; Conraths FJ; Harnett W; Buttner DW; Parkhouse RM
Am J Trop Med Hyg; 1996 May; 54(5):490-7. PubMed ID: 8644904
[TBL] [Abstract][Full Text] [Related]
39. Macro- and microfilariae in nodules from onchocerciasis patients in the Yemen Arab Republic.
Büttner DW; Rácz P
Tropenmed Parasitol; 1983 Jun; 34(2):113-21. PubMed ID: 6879705
[TBL] [Abstract][Full Text] [Related]
40. Doxycycline in the treatment of human onchocerciasis: Kinetics of Wolbachia endobacteria reduction and of inhibition of embryogenesis in female Onchocerca worms.
Hoerauf A; Mand S; Volkmann L; Büttner M; Marfo-Debrekyei Y; Taylor M; Adjei O; Büttner DW
Microbes Infect; 2003 Apr; 5(4):261-73. PubMed ID: 12706439
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
